Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-ne…
An institutional-grade, numbers-driven thesis on ONCY — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Oncolytics Biotech Inc. (ONCY) 49/100 with a 12-month base-case forecast of $0.53 — -36.5% versus the current price of $0.83. Oncolytics Biotech Inc. trades at $0.83 in the Healthcare sector, with a market capitalisation of $83.7M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for ONCY is $0.53, implying -36.5% versus the current price. The model's 12-month scenario range runs from $0.38 (bear) to $0.71 (bull), with a base case of $0.53.
On the fundamentals, Oncolytics Biotech shows a P/E of -3.4, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks ONCY's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ONCY currently carries a TradersQuant composite score of 49/100, which we read as a cautious signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $0.53 implies -36.5% from $0.83. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for ONCY is $0.53, about -36.5% versus the latest price of $0.83. Consensus is based on 10 analysts.
TradersQuant's 12-month model forecast for ONCY is a base case of $0.53, ranging from $0.38 (bear) to $0.71 (bull), an expected return of -36.8%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ONCY over the next 12 months is $0.53 in the base case (bear $0.38, bull $0.71), versus today's price of $0.83. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ONCY — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ONCY's fair value at $1.04, implying +24.3% of expected upside versus the current price.
Oncolytics Biotech does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
